Literature DB >> 7973509

[TBE-immunoglobulins--a critical assessment of efficacy].

C Aebi1, U B Schaad.   

Abstract

Since there is no specific treatment for tick-borne encephalitis (TBE), immunoprophylaxis is used in endemic areas for controlling this disease. Active immunization has been shown to be effective and safe, and a restrictive immunization policy is generally accepted in Switzerland. However, the use of TBE-immunoglobulin for passive immunization after tick exposure is controversial. This article demonstrates that the published reports on the protection rate of TBE-immunoglobulin do not stand up to critical analysis. Efficacy has never been proved. Therefore, the use of TBE-immunoglobulin must be based upon practical or theoretical arguments. Routine administration of this preparation in endemic areas cannot be recommended.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7973509

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  5 in total

Review 1.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Severe tick-borne encephalitis following passive immunization.

Authors:  K Waldvogel; W Bossart; T Huisman; E Boltshauser; D Nadal
Journal:  Eur J Pediatr       Date:  1996-09       Impact factor: 3.183

Review 3.  Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.

Authors:  Göran Günther; Mats Haglund
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model.

Authors:  T R Kreil; M M Eibl
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Post-exposure administration of chimeric antibody protects mice against European, Siberian, and Far-Eastern subtypes of tick-borne encephalitis virus.

Authors:  Andrey L Matveev; Irina V Kozlova; Oleg V Stronin; Yana A Khlusevich; Elena K Doroshchenko; Ivan K Baykov; Oksana V Lisak; Ljudmila A Emelyanova; Olga V Suntsova; Vera A Matveeva; Julia S Savinova; Nina V Tikunova
Journal:  PLoS One       Date:  2019-04-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.